News

tMMJ-002, a cannabis investigational product for the treatment of Huntington’s disease, has been granted Orphan Drug designation by the U.S. Food and Drug Administration, announced its developer MMJ International Holdings. This new status is expected to expedite the clinical development, regulatory review, and potential marketing approval of the therapy, which…

About 100 scientists, researchers, pharmaceutical executives, and others will converge on Austria’s capital city early next month for the 2nd International Congress on Advanced Treatments in Rare Diseases. The March 4-5 meeting, to take place at the Hilton Am Stadtpark Vienna, features 27 speakers on a variety of disorders…

Impairment in emotional recognition — the process of identifying human emotion, most typically from facial expressions, particularly happy ones — seems to be linked with apathy in Huntington’s disease patients, a study showed. The article, “Apathy Associated With Impaired Recognition of Happy Facial Expressions…

In support of ongoing development of a prospective new therapy for Huntington’s disease, the California Institute for Regenerative Medicine (CIRM) has awarded University of California, Irvine (UCI) investigators $6 million in funding. The hope is that the two-year study, which continues development of a human neural stem…

Several small molecules have been identified by the Alborada Drug Discovery Institute as potential inhibitors to help halt the underlying mechanisms that drive the development of neurodegenerative diseases such as Huntington’s and Parkinson’s disease. Silencing phosphatidylinositol 5-phosphate 4 (PI5P4) kinases has been shown to enhance the natural cleaning system of cells, called autophagy,…

Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces, wear…

Dysfunction in the development and maturation of the brain’s primary support cells, know as glial cells, contributes to nerve cell damage in a a mouse model of Huntington’s disease. “These new findings help pinpoint how the genetic flaw in Huntington’s gives rise to glial cell dysfunction, which impairs the development and…

The upcoming Phase 3 trial of RG6042 will test whether lowering the levels of a mutant form of huntingtin (mHTT) translates into functional, motor and cognitive benefits for people with Huntington’s disease. Potential benefits could also help advance gene-silencing approaches in other neurodegenerative diseases. “Deep down, we all…

A Phase 3 clinical trial is enrolling adults with Huntington’s disease across the United States and Canada to test the potential of the investigational therapy RG6042. The GENERATION HD1 study (NCT03761849) will run in 16 U.S. states and five Canadian provinces, and include about 660 people from 25…

uniQure is launching a Phase 1/2 trial in the United States to evaluate the safety and effectiveness of its Huntington’s disease investigational gene therapy AMT-130. This follows recent approval of an investigational new drug (IND) application for AMT-130 by the U.S. Food and Drug Administration (FDA). “The…